Form 4: Vera Therapeutics CCO Granted Significant Equity Awards

Vera Therapeutics' Chief Commercial Officer, Laurence Matthew Skelton, was granted 20,000 restricted stock units and options to purchase 40,000 shares of Class A Common Stock.

Summary

• Laurence Matthew Skelton, Chief Commercial Officer of Vera Therapeutics, Inc., acquired 20,000 shares of Class A Common Stock through Restricted Stock Units (RSUs) on February 4, 2026.
• These RSUs were granted under the Issuer's 2021 Equity Incentive Plan and will vest in four equal annual installments, starting on February 20, 2027, and continuing through 2030, contingent on continuous service.
• Skelton also acquired options to purchase 40,000 shares of Class A Common Stock with an exercise price of $42.74 per share on February 4, 2026.
• The stock options will vest monthly, with 1/48th of the shares becoming exercisable on March 4, 2026, and subsequent monthly vesting, also subject to continuous service.
• The stock options have an expiration date of February 3, 2036.
• Following these transactions, Skelton beneficially owns 65,800 shares of Class A Common Stock and 40,000 stock options directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a routine executive compensation event that aligns management's interests with shareholders, without indicating any immediate operational or financial performance changes.

Positives

• The equity grants align the Chief Commercial Officer's long-term financial interests with those of the shareholders, incentivizing sustained performance.
• The significant number of shares and options granted indicates a commitment to retaining key management personnel.

Negatives

• The grants do not represent an immediate cash benefit to the officer, as they are subject to multi-year vesting schedules.
• The value of the awards is dependent on the future stock performance of Vera Therapeutics, introducing market risk.

Risks

• The vesting of both the RSUs and stock options is contingent upon the Reporting Person's continuous service through each vesting date, meaning forfeiture if employment ceases.
• The value realized from the stock options is dependent on the stock price exceeding the exercise price of $42.74, posing a risk if the stock underperforms.

Future Outlook

The equity grants signify a long-term incentive structure for the Chief Commercial Officer, aligning their future compensation with the company's stock performance and strategic goals over the next several years, with vesting extending through 2030 for RSUs and options expiring in 2036.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries. This approach is widely used to attract, retain, and motivate key executives by linking their financial success directly to the company's long-term share price performance and strategic achievements.

Comparison to Industry Standards

• The structure of multi-year vesting for both RSUs (four years) and stock options (monthly over four years) is consistent with typical executive compensation packages designed to promote long-term retention and performance in the biotech sector.
• Without specific peer company data for Chief Commercial Officer compensation at a similar stage of development as Vera Therapeutics, a direct quantitative comparison of the grant size is not feasible. However, the use of both RSUs and stock options is a common dual-pronged approach to equity incentives.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term shareholder value creation.
• Employees: No direct impact mentioned, but general positive signal regarding executive retention.

Next Steps

• Continued service of the Chief Commercial Officer to ensure vesting of RSUs and stock options.
• Monitoring of Vera Therapeutics' stock performance relative to the stock option exercise price of $42.74.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Chief Commercial Officer, Executive Compensation